Novo Nordisk, ASML and Co.: New hype stocks: These are the “Granolas”

The shares of the European heavyweights have not all performed equally well. Over the past twelve months, the top performer Novo Nordisk achieved a 67 percent increase, largely thanks to the hype surrounding its Wegovy weight loss injection. The red lantern goes to Roche with minus 14 percent over the twelve months. Four of the eleven companies could not keep up with the 7.5 percent of the Stoxx Europe 600 (Roche, Nestlé, Sanofi, AstraZeneca), one was on par (LVMH). That means: The excess return comes from the other six, with Novo Nordisk, SAP and ASML standing out with more than 50 percent each.